THE ARISING · Markets & Strategy · Long Reads
Big Pharma Filled the Speaker List at a Major Aging-Drug Meeting
The 2026 Aging Research and Drug Discovery meeting at Harvard drew speakers from more than a dozen major drug companies, the FDA and big investors. Interest in aging biology is real; an approved aging drug is still years away. The organizer describes the meeting as the world's largest dedicated to longevity biotechnology, a framing no independent count backs up.
A decade ago, aging research meetings were smaller affairs. In October, the speaker list at a major aging-drug meeting read like a pharma industry directory. That signals attention, not proof that investment or clinical outcomes will follow.
The 13th Aging Research and Drug Discovery meeting, known as ARDD, ran October 1 to 3, 2026, at Harvard's David Rubenstein Treehouse in Boston. It is organized by Insilico Medicine, an AI drug discovery company. Its chairs include Vadim Gladyshev of Harvard Medical School and Alex Zhavoronkov of Insilico.
Eli Lilly and Insilico were the top-tier sponsors. AbbVie, BioAge, Human Longevity and others sponsored at lower tiers. McKinsey Health Institute was the knowledge partner.
The published speaker roster includes scientists and executives from:
The published program includes speakers from Lilly, Novartis, Pfizer, Takeda, GSK, AstraZeneca, Novo Nordisk, Genentech, Roche, Astellas, Daiichi Sankyo and Lundbeck. The October 2 Pharma Chief Executive Panel, moderated by TIME's Alice Park, lists Fiona Marshall, Ariel Feldstein, Elcin Barker Ergun, Christophe Weber and Stéphane Bancel. Other sessions include FDA officials and ARPA-H, alongside academic researchers and biotechnology companies.
Speaking slots do not equal strategy, but deals do. In March 2026, Insilico announced a research collaboration with Lilly worth up to about $2.75 billion, including $115 million upfront, according to the company's release.
Some outlets framed that deal as Lilly's big bet on aging. The release itself never uses the word. It names multiple therapeutic areas. That gap is typical: pharma studies aging biology but files for specific diseases.
Large pharmaceutical companies have the resources to run long, costly outcome trials. Their presence creates an opportunity for better evidence, but it does not guarantee trials, approvals or insurance coverage.
The heavy FDA presence is also notable. Regulators showing up to an aging meeting suggests the conversation about biomarkers and new endpoints is active, even if rules have not changed.
The program itself pointed toward the clinic. The first day held a longevity medicine forum and a workshop for the XPRIZE Healthspan competition, alongside several clinical-trial and regulatory sessions. Later days covered AI in drug discovery, virtual models of aging cells and even pet longevity, a field where some aging drugs may reach the market first.
For patients, the practical upshot is modest for now. A conference program does not establish that an intervention works or predict when it might reach a pharmacy.
• Sponsorship shapes the stage. The organizer and top sponsor are business partners. • Open question: whether trials of drugs that affect aging biology will demonstrate meaningful clinical benefits beyond their established indications.
• Follow-up research and trial reports from ARDD 2026 speakers. • Any FDA statement on biomarkers or endpoints for aging trials. • First clinical candidates from the Lilly–Insilico collaboration. • Whether more pharma companies form dedicated aging units. Not financial advice.